NCT00479167终止2 期
A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodg
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- The Primary Objective of This Study is to Determine the Maximum Tolerated Dose (up to 1.6 mg/m2) of Bortezomib Combined With Tositumomab and Iodine I 131 Tositumomab
研究概览
简要总结
The purpose of this study is to determine what dose of bortezomib in combination with tositumomab I-131 is tolerable whether bortezomib and Tositumomab I-131 are effective in the treatment of relapsed or refractory non-hodgkin's lymphoma (NHL). Both agents are effective in treating relapsed and refractory NHL. Administer of the agents together may sensitize the cells to the radiation from Tositumomab I-131.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Previously treated or relapsed follicular lymphoma. One prior therapy required.
- •Bi-dimensionally measurable disease with at least one lesion measuring > 2.0 X 2.0cm by CT scan or evaluable disease.
- •CD20+ at time of diagnosis or subsequently.
- •Platelet count > 100,000/uL, ANC > 1000/uL.
- •Transaminases less than two-fold normal range.
- •Adequate renal function defined as <1.5 X upper limit of normal
- •HAMA negative
- •ECOG performance status 0, 1,
- •Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.
- •Male subject agrees to use an acceptable method for contraception for the duration of the study.
- •Negative Hepatitis profile screening
排除标准
- •Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (see section 8.4), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant.
- •Patient has hypersensitivity to boron or mannitol.
- •Greater than 25% of the intratrabecular marrow space involved by lymphoma in bone marrow biopsy specimens
- •Hypocellular bone marrow (≤15% cellularity or marked reduction in bone marrow precursors).
- •Prior myeloablative therapy.
- •History of failed stem cell collection.
- •Prior radiotherapy to fields encompassing more than 25% of the blood-forming marrow.
- •Prior chemotherapy, biologic therapy, radiation therapy or steroid therapy for NHL within three weeks prior to screening procedures. Six weeks for nitrosureas. Subjects receiving low doses of steroids for non-neoplastic indications may enter the study ("low dose steroids" is defined as ≤10 mg of prednisone or equivalent per day).
- •Prior Radioimmunotherapy or bortezomib.
- •Prior malignancy other than lymphoma, except for adequately treated basal cell or squamous cell skin cancer, in situ uterine cervical cancer, or other cancer for which the subject has been disease-free for five years.
- •Evidence of active infection requiring intravenous antibiotics at the time of study enrollment.
- •Known HIV infection.
- •Known brain or leptomeningeal metastases.
- •Active obstructive hydronephrosis.
- •Known Type I hypersensitivity or anaphylactic reactions to murine proteins or any component of the Iodine I 131 tositumomab therapeutic regimen.
- •Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women.
- •Patient has received other investigational drugs with 14 days before enrollment
- •Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
- •Patient has Grade 2 peripheral neuropathy within 14 days before enrollment.
研究组 & 干预措施
Bortezomib and Tositumomab I-131
Experimental
干预措施: Bortezomib and Tositumomab I-131 (Drug)
结局指标
主要结局
The Primary Objective of This Study is to Determine the Maximum Tolerated Dose (up to 1.6 mg/m2) of Bortezomib Combined With Tositumomab and Iodine I 131 Tositumomab
时间窗: Study terminated.
次要结局
- To Further Explore the Toxicity and Efficacy of Bortezomib Combined With Tositumomab and Iodine I 131 Tositumomab and Assess the Tolerability of Bortezomib After Tositumomab(Study Terminated.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT00972712Emory University12
已完成
2 期
A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple MyelomaMultiple MyelomaNCT00872521Janssen-Cilag Pty Ltd107
已完成
1 期
A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)Multiple MyelomaNCT00985959Janssen Pharmaceutical K.K.101
已完成
1 期
A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant PatientsHematopoetic Stem Cell TransplantNCT01926899Indiana University15
进行中（未招募）
1 期
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH TrialRecurrent Plasma Cell MyelomaRefractory Plasma Cell MyelomaNCT05514990University of Southern California10